Cogent Biosciences Inc - The overall tolerability of adding Bezuclastinib to sunitinib is still good and safety is encouraging
Cogent Biosciences Inc——将Bezuclastinib加入舒尼替尼的总体耐受性仍然良好安全性令人鼓舞
Cogent Biosciences Inc - The overall tolerability of adding Bezuclastinib to sunitinib is still good and safety is encouraging
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.